Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uveal Melanoma 6Retinal Diseases 2Melanoma 2Macular Edema 2von Hippel-Lindau Disease 1Retinoblastoma 1Neurofibromatosis 1 1Neurofibroma 1Neoplasms 1Macular Degeneration 1Glaucoma, Neovascular 1Conjunctival Neoplasms 1Choroid Diseases 1

Interventions

AZD 6244 19trametinib 5Lovastatin 5Deoxycholic Acid 4mirdametinib 3Lasers, Solid-State 3pirfenidone 2fludarabine 2binimetinib 2Vincristine 2Vinblastine 2Transcranial Direct Current Stimulation 2Specimen Handling 2Sirolimus 2Polidocanol 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Lasers 2Lamotrigine 2Inhalation 2Everolimus 2Carboplatin 2Biopsy 2Acetylcysteine 2tipifarnib 1thymoglobulin 1talimogene laherparepvec 1pomalidomide 1peginterferon alfa-2b 1omipalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurofibromatosis 1 × Ranibizumab × Clear all
NCT00657202 2016-07-07

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

Massachusetts General Hospital

Phase EARLY_PHASE1 Completed
11 enrolled
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡